ArticleMicrobiology spectrum2026
Performance of prototype serological immunoassays for foot-and-mouth disease virus using G-H loop peptides and stabilized virus-like particles.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Inter-serotype cross-reactivity of foot-and-mouth disease (FMD) antibody enzyme-linked immunosorbent assays (ELISAs) can exceed 50%, leading to incorrect serotyping of outbreaks with implications for vaccine selection. In this study, synthetic peptides that mimic the hypervariable G-H loop of FMD viruses (FMDVs) that currently circulate in East Africa (O, A, SAT1, and SAT2) were evaluated as capture antigens in ELISAs (pELISAs). A panel of monovalent bovine sera was tested using these novel assays in parallel with separate ELISAs that utilized stabilized virus-like particles (VLPs). Virus neutralization tests using the same viruses were used to benchmark the status of the sera, which revealed evidence of cross-reactivity for the serotype O and SAT2 antigens (encompassing 2/19 and 3/19 of the heterologous sera, respectively). Equivalent diagnostic serotype sensitivity was observed for prototype peptide and VLP ELISAs for serotype O and SAT1 antigens (86% and 100%, respectively), while there was higher diagnostic serotype sensitivity for the VLP ELISAs targeting serotypes A and SAT2 compared to the corresponding pELISAs (86% vs 71% and 100% vs 86%, respectively). The serotype specificity of these tests ranged from 71% to 79% and 52% to 89% for the pELISA and VLP ELISA formats, respectively. Peptides offer a simple, biosafe, and cost-effective approach to present FMDV-specific epitopes, and these initial findings suggest that peptide ELISAs could be a promising approach to develop serological ELISA assays to present authentic epitopes in comparison to ELISAs that use full capsid VLPs. IMPORTANCE: This study marks a significant advancement in the development of safe, affordable, and scalable diagnostic tools for foot-and-mouth disease virus. By employing the G-H loop, a critical epitope on the receptor-binding domain within the viral capsid, we demonstrate that the G-H loop peptide-based ELISAs can effectively mimic and present authentic epitopes as the full virus particles in serological assays. This approach offers several important benefits:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.